These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1. Letter: Dosage of antipsychotic drugs. Ericksen SE; Hurt SW; Davis JM N Engl J Med; 1976 Jun; 294(23):1296-7. PubMed ID: 4732 [No Abstract] [Full Text] [Related]
2. Longterm maintenance therapy with depot haloperidol in schizophrenia. Zbytovský J Homeost Health Dis; 1991; 33(5-6):287. PubMed ID: 18265499 [No Abstract] [Full Text] [Related]
3. Evaluation of optimal doses of a neuroleptic: preliminary results. Potkin SG; Urbanchek MS; Kirch DG; Bunney WE Clin Neuropharmacol; 1986; 9 Suppl 4():437-9. PubMed ID: 2882848 [No Abstract] [Full Text] [Related]
4. Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. arap Mengech HN; Wazome EG East Afr Med J; 1984 Jun; 61(6):435-8. PubMed ID: 6152736 [No Abstract] [Full Text] [Related]
5. [Clinical and economic approach to evaluation of the effectiveness of moditen-depot and haloperidol decanoate in the maintenance therapy of attack-like schizophrenia]. Ushakov IuV; Kravchenko NE; Kopeĭko GI; Kalugina LI; Mirzoian MG Zh Nevropatol Psikhiatr Im S S Korsakova; 1990; 90(7):99-104. PubMed ID: 1979463 [TBL] [Abstract][Full Text] [Related]
6. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics. Möller HJ; Kissling W Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841 [No Abstract] [Full Text] [Related]
8. Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Reschke RW Dis Nerv Syst; 1974 Mar; 35(3):112-5. PubMed ID: 17894080 [TBL] [Abstract][Full Text] [Related]
9. Comment on 'reduced haloperidol does not interfere with antipsychotic activity of halperidol in the treatment of acute schizophrenia'. Altamura AC; Bareggi SR Int Clin Psychopharmacol; 2000 Sep; 15(5):303-4. PubMed ID: 10993133 [No Abstract] [Full Text] [Related]
11. Amisulpride: a review of its efficacy in schizophrenia. Möller HJ Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307 [TBL] [Abstract][Full Text] [Related]
12. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate. Kane JM J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088 [TBL] [Abstract][Full Text] [Related]
13. [Bromperidol decanoate in the residual phase of schizophrenia]. Smeraldi E; Cocconcelli C; Canova L; Faravelli C; Marchetti FP; Mariani G; Rapisarda V Minerva Psichiatr; 1996 Mar; 37(1):39-44. PubMed ID: 8926856 [TBL] [Abstract][Full Text] [Related]
14. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
15. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Miceli JJ; Tensfeldt TG; Shiovitz T; Anziano RJ; O'Gorman C; Harrigan RH Clin Ther; 2010 Mar; 32(3):472-91. PubMed ID: 20399985 [TBL] [Abstract][Full Text] [Related]
16. [Acute psychosis: in an emergency always still haloperidol?]. Möller HJ Dtsch Med Wochenschr; 2008 Jan; 133(3):96. PubMed ID: 18186013 [No Abstract] [Full Text] [Related]
17. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910 [TBL] [Abstract][Full Text] [Related]
18. Blood cells show differences in DNA methylation in schizophrenia patients. Wilkinson J Epigenomics; 2012 Jun; 4(3):247-8. PubMed ID: 22690659 [No Abstract] [Full Text] [Related]
19. [Should we discontinue the use of Serenase?]. Kragh J Ugeskr Laeger; 2005 Nov; 167(48):4579; author reply 4579. PubMed ID: 16324450 [No Abstract] [Full Text] [Related]
20. [Selection and dosages of therapeutic agents for the early stage of schizophrenia]. Yagi G; Watanabe E; Takano H Seishin Shinkeigaku Zasshi; 1999; 101(11):908-15. PubMed ID: 10756682 [No Abstract] [Full Text] [Related] [Next] [New Search]